摘要
目的 研究肝硬化患者红细胞补体受体I型分子(Complement receptor type 1,CR1)密度相关基因多态性、数量表达及活性的变化。方法 采用PCR和Hind Ⅲ酶切技术测定红细胞CR1分子基因多态性,采用酶联法定量测定红细胞CR1分子的数量,采用红细胞天然免疫粘附功能实验测定红细胞CR1分子粘附活性。结果 肝硬化患者红细胞CR1分子密度相关基因多态性与正常人相比,差异无显著性意义(P>0.05),但其红细胞CR1分子的数量表达及活性明显低于正常健康人群(P<0.01),失代偿性乙肝后肝硬化患者的CR1分子数量明显低于代偿性乙肝后肝硬化患者(P<0.05),但肝功正常的肝硬化患者红细胞CR1分子数量与正常人比较无明显变化(P>0.05)。结论 肝硬化患者红细胞CR1分子数量表达及活性缺陷可能是后天因素引起;测定肝硬化患者红细胞CR1分子的数量对临床病情判断及发展预测有重要参考价值。
Objective To study the changes of genomic density polymorphism, quantitative expression and adherence activity of complement receptor type 1 (CR1) on erythrocytes in patients with cirrhosis. Methods Polymerase chain reaction (PCR) and Hind Ⅲ restriction enzyme digestion, quantitative assay of ECRl and erythrocyte immune adherence activity test were used. Results The spot mutation rate (25.0% -30.3%) of ECRl density gene in patients with cirrhosis was not significantly different from that in healthy individuals (28.0%). The amounts of ECRl in padents with cirrhosis, except for the diseases with normal liver function, was significantly lower than that in healthy individuals ( P < 0.01) .The quantitative expression of ECRl in decompensated cirrhosis was significantly lower than that in compensated cirrho- sis ( P < 0.05 ) , and there is a strong relationship between the expression of ECRl and the activity of development in cirrhosis. Conclusions Defective expression of ECRl in cirrhosis is acquired through central and/or peripheral mechanisms.It is important to study the quantitative expression ECR1 in assessment and prediction of with cirrhosis development.
出处
《武警医学》
CAS
2003年第4期205-207,共3页
Medical Journal of the Chinese People's Armed Police Force
